Company profile
Exelixis
EXEL · NASDAQ
Share price · EXEL
$53.12+3.28 (+6.58%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Multi-kinase inhibitor (VEGFR/PDGFR/KIT)Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | 5T4 (trophoblast glycoprotein, TPBG)Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | VEGFR2; MET; AXL; MER; TYRO3Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.